CRISPR Therapeutics AG (CRSP) stock
CRSPNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$42.24−0.38 (-0.89%)
Close on Nov 13, 2026Market cap $4.08BP/E –Yield –
CRISPR Therapeutics statistics
81 measures from SEC filings and the closing price. Hover a name for the formula; the last column is the median of companies in the same industry group.
Important dates
- Next earnings
- Feb 11, 2027 (estimated, after the close)
- Last ex-dividend date
- No dividends
- Fundamentals through
- Sep 30, 2026
- Share price as of
- Nov 13, 2026
Valuation ratiosIndustry
- P/TBV Ratio
- 2.48
- 2.22
Enterprise valuationIndustry
- EV / Sales
- 71.97
- 2.57
Share statisticsIndustry
- Shares Change (YoY)
- 9.96%
- 10.8%
- Shares Change (QoQ)
- 0.20%
- 0.50%
- Float
- 94M
- 49M
- Shares Held by Insiders
- 2.72%
- 11.7%
- Shares Held by Institutions
- 78.9%
- 56.4%
Short sellingIndustry
- Short Interest
- 17M
- –
- Short Interest Change
- 4.54%
- -0.80%
- Short % of Float
- 18.3%
- 9.01%
- Short % of Shares Outstanding
- 17.8%
- 6.30%
- Days to Cover
- 13.09
- 5.15
Stock price statisticsIndustry
- 52-Week High
- $63.45
- –
- 52-Week Low
- $41.75
- –
- 20-Day Moving Average
- $49.31
- –
- 50-Day Moving Average
- $52.09
- –
- 200-Day Moving Average
- $52.53
- –
- Average True Range (14)
- $2.68
- –
- Price Change (1 Week)
- -15.6%
- -1.15%
- Price Change (1 Month)
- -18.0%
- -4.87%
- Price Change (3 Months)
- -22.2%
- -21.0%
- Price Change (6 Months)
- -12.7%
- -20.6%
- Price Change (YTD)
- -19.5%
- -23.6%
- Price Change (1 Year)
- -19.1%
- -22.4%
- Price Change (3 Years)
- -23.6%
- -29.5%
- Price Change (5 Years)
- -52.5%
- -77.9%
- Price Change (10 Years)
- 140.0%
- -65.4%
- Average Volume (10 Days)
- 2M
- –
- Average Volume (20 Days)
- 2M
- –
- Average Volume (90 Days)
- 2M
- –
- Relative Volume
- 1.17
- 0.70
- Relative Strength Index (14)
- 31.9
- 43.4
- Volatility (1 Year)
- 58.2%
- 80.1%
- Beta (5 Years)
- 1.37
- 1.07
MarginsIndustry
- Pretax Margin
- -1802.2%
- -11.6%
- EBITDA Margin
- -2041.3%
- -27.7%
- FCF Margin
- -1496.6%
- -9.56%
Returns on capitalIndustry
- Return on Equity (ROE)
- -25.6%
- -49.9%
- Return on Assets (ROA)
- -19.0%
- -40.6%
- Return on Capital Employed (ROCE)
- -22.0%
- -37.9%
Financial positionIndustry
- Current Ratio
- 16.21
- 3.30
- Quick Ratio
- 16.12
- 2.39
GrowthIndustry
- Revenue Growth (YoY)
- -34.3%
- 6.82%
- Revenue Growth (3Y CAGR)
- 43.1%
- 2.25%
- Revenue Growth (5Y CAGR)
- 37.3%
- 6.41%
EfficiencyIndustry
- Asset Turnover
- 0.01
- 0.40
- Revenue Per Employee
- $64.05K
- $429.29K
- Profits Per Employee
- -$1.16M
- -$689.41K
- Employee Count
- 393
- 74
- WACC
- 12.0%
- 10.2%
Income statement (TTM)Industry
- Pretax Income
- -$453.65M
- -$12.95M
Balance sheetIndustry
- Net Cash (Debt)
- $2.27B
- $17.76M
- Net Cash Per Share
- $23.50
- $0.80
- Equity (Book Value)
- $1.65B
- $53.89M
- Book Value Per Share
- $17.04
- $1.50
- Tangible Book Value
- $1.65B
- $27.13M
- Working Capital
- $2.14B
- $79.99M
Cash flow (TTM)Industry
- Capital Expenditures
- -$2.08M
- -$1.00M
- FCF Per Share
- -$3.90
- -$0.42
Dividends and yieldsIndustry
- Earnings Yield
- -11.2%
- -21.8%
- FCF Yield
- -9.22%
- -9.44%
- Buyback Yield
- -2.71%
- -0.76%
- Shareholder Yield
- -2.71%
- 0.00%
Taxes and interestIndustry
- Income Tax
- $2.49M
- $73.00K
Scores and fair valueIndustry
- Altman Z-Score
- 1.78
- 0.23
- Piotroski F-Score
- 2
- 4
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | CRSP | S&P 500 | Difference | CRSP per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -15.7% | -3.0% | −12.7 pts | ||
| 3 months | -21.8% | -2.8% | −19.0 pts | ||
| Year to date | -19.5% | +11.5% | −30.9 pts | ||
| 1 year | -17.4% | +13.5% | −30.8 pts | ||
| 3 years | -18.8% | +77.7% | −96.5 pts | -6.7% | +21.1% |
| 5 years | -52.5% | +72.6% | −125.1 pts | -13.8% | +11.5% |
| 10 years | +141.4% | +308.2% | −166.8 pts | +9.2% | +15.1% |
Short interest
Shares sold short and not yet covered, reported by brokers to FINRA twice a month. Latest settlement date Oct 30, 2026.
17M CRSP shares were sold short on Oct 30, 2026, up 4.5% from the previous report, or 18.27% of the shares available to trade. At recent volumes it would take 13.1 days to buy them back. Over the last 20 sessions, 52.5% of the volume reported to FINRA was short selling.
| Settlement date | Shares short | Change | Avg. daily volume | Days to cover |
|---|---|---|---|---|
| Oct 30, 2026 | 17,189,067 | +4.5% | 1,312,645 | 13.1 |
| Oct 15, 2026 | 16,442,415 | -12.0% | 1,606,803 | 10.2 |
| Sep 30, 2026 | 18,679,198 | -2.1% | 1,949,970 | 9.6 |
| Sep 15, 2026 | 19,071,093 | +1.6% | 1,152,800 | 16.5 |
| Aug 31, 2026 | 18,769,995 | +0.1% | 1,749,800 | 10.7 |
| Aug 14, 2026 | 18,744,855 | -0.4% | 1,203,269 | 15.6 |
| Jul 31, 2026 | 18,815,663 | -5.0% | 1,634,000 | 11.5 |
| Jul 15, 2026 | 19,808,194 | -2.9% | 1,713,855 | 11.6 |
| Jun 30, 2026 | 20,397,833 | -23.2% | 1,750,460 | 11.7 |
| Jun 15, 2026 | 26,572,400 | +22.6% | 1,625,617 | 16.4 |
| May 29, 2026 | 21,672,640 | -20.6% | 1,763,869 | 12.3 |
| May 15, 2026 | 27,293,997 | +21.4% | 1,650,520 | 16.5 |
Ratios use trailing-twelve-month results and the latest balance sheet. How we calculate.
See a number that looks wrong?